Phase 2
Completed N=70
Treatment of Patients With Blepharitis and Facial Rosacea
Blepharitis · Meibomianitis · Dry Eye Disease
Source: ClinicalTrials.gov NCT00560703 ↗
Enrolled (actual)
70
Serious AEs
2.9%
Results posted
Jan 2012
Primary outcomePrimary: Change in Bulbar Conjunctival Hyperemia — -0.61; -0.60 Scores on a scale — p=0.578
Summary
To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Bulbar Conjunctival Hyperemia |
-0.61; -0.60 | 0.578 |
| PRIMARY Change in Ocular Surface Disease Index (OSDI) |
-5.15; -8.70 | 0.293 |
Eligibility Criteria
Inclusion Criteria
- blepharitis
- facial rosacea
Exclusion Criteria
- pregnant or nursing women
- allergy to tetracyclines
- recent eye surgery
- past or current use of isotretinoin
- patients who are achlorhydric
- patients who have had gastric by-pass surgery
Data sourced from ClinicalTrials.gov (NCT00560703). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.